Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | SVP, Finance & Corp Controller | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ZEVRA THERAPEUTICS, INC.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.40 · Expires 2036-05-27 | Direct | 40,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 40,000 · Balance 40,000 F1: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The option will vest and become exercisable in four equal annual installments beginning on March 1, 2027, subject to the Reporting Person's continued service on such vesting date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2026-05-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-28 · Grant · Acquired 20,000 · Balance 20,000 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3: The restricted stock units will vest and settle as to one third of the restricted stock units on March 1, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The option will vest and become exercisable in four equal annual installments beginning on March 1, 2027, subject to the Reporting Person's continued service on such vesting date.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: The restricted stock units will vest and settle as to one third of the restricted stock units on March 1, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001434647-26-000037 · wk-form4_1780085770.xml · derivative · entry 2 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on March 1, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. F3 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on March 1, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 28, 2026 Filed May 29, 2026 20:16 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $11.40 | $0.00 |
DisclosureSEC source: 0001434647-26-000037 · wk-form4_1780085770.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The option will vest and become exercisable in four equal annual installments beginning on March 1, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 21:27 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 3,000 | $9.18 | $27,548.10 |
DisclosureSEC source: 0001698328-26-000004 · wk-form4_1770240439.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,590 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 3/28/2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.93 to $9.52. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 11,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001698328-26-000002 · wk-form4_1770070795.xml · derivative · entry 5 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,668 Underlying: Common Stock · 11,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date. F5 · derivative.expiration_date: One third of the restricted stock units vested and settled on each of January 31, 2025 and January 31, 2026. The remaining one third of the shares will vest and settle on January 31, 2027, subject to the Reporting person's continued service through such vesting date. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 11,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001698328-26-000002 · wk-form4_1770070795.xml · nonDerivative · entry 3 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 6,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001698328-26-000002 · wk-form4_1770070795.xml · derivative · entry 4 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,667 Underlying: Common Stock · 6,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. F4 · derivative.expiration_date: One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the shares will vest and settle in equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 1,750 | $8.82 | $15,442.00 |
DisclosureSEC source: 0001698328-26-000002 · wk-form4_1770070795.xml · nonDerivative · entry 2 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,924 F2 · kind: Adoption date of referenced 10b5-1(c) plan is: 3/28/2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $8.62 to $8.995. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 30, 2026 Filed Feb 2, 2026 22:19 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 6,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001698328-26-000002 · wk-form4_1770070795.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 13, 2025 Filed Feb 14, 2025 22:57 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | SaleCommon Stock | 3,000 | $7.86 | $23,587.80 |
DisclosureSEC source: 0001437749-25-004070 · rdgdoc.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,341 F1 · kind: Adoption date of referenced 10b5-1(c) plan is: 10-15-2024 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 22:24 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionRestricted Stock Unit · Derivative | 11,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002629 · rdgdoc.xml · derivative · entry 2 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,334 Underlying: Common Stock · 11,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle inequal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. F2 · derivative.expiration_date: The first tranche of the restricted stock units vested and settled on January 31, 2025, and the remaining two tranches of the restricted stock units will vest and settle inequal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 22:24 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | Exercise / conversionCommon Stock | 11,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-25-002629 · rdgdoc.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 22:24 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 19,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-002629 · rdgdoc.xml · derivative · entry 4 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 30, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. F4 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 30, 2026, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's continued service through such vesting date. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 22:24 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 38,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001437749-25-002629 · rdgdoc.xml · derivative · entry 3 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Finance & Corp Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-01-29 F3 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| January 31, 2024 Filed Feb 3, 2024 01:17 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantRestricted Stock Unit · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-003031 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Grant to the Reporting Person of restricted stock units ("RSU"). F2 · derivative.exercise_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to one third of the restricted stock units on January 31, 2025, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting person's ongoing employment. Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 11:57 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 100 | $4.14 | $413.50 |
DisclosureSEC source: 0001437749-23-006278 · rdgdoc.xml · nonDerivative · entry 2 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,449 Read SEC document |
| March 10, 2023 Filed Mar 13, 2023 11:57 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | PurchaseCommon Stock | 1,100 | $4.14 | $4,553.67 |
DisclosureSEC source: 0001437749-23-006278 · rdgdoc.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,349 Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 02:45 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 136,986 | $0.00 Strike: $4.54 | $0.00 |
DisclosureSEC source: 0001437749-23-000913 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,986 Underlying: Common Stock · 136,986 shares Expires 2033-01-08 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 6, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:17 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 50,092 | $0.00 Strike: $7.17 | $0.00 |
DisclosureSEC source: 0001437749-22-002401 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,092 Underlying: Common Stock · 50,092 shares Expires 2032-01-31 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on February 1, 2023 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 20:27 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 44,023 | $0.00 Strike: $9.06 | $0.00 |
DisclosureSEC source: 0001437749-21-020859 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,023 Underlying: Common Stock · 44,023 shares Expires 2031-08-19 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on August 20, 2022 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 00:04 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 4,000 | $0.20 | $800.00 |
DisclosureSEC source: 0001437749-20-005367 · rdgdoc.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Read SEC document |
| March 10, 2020 Filed Mar 10, 2020 20:34 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 7,657 | $0.26 | $1,952.54 |
DisclosureSEC source: 0001437749-20-004693 · rdgdoc.xml · nonDerivative · entry 3 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Read SEC document |
| March 10, 2020 Filed Mar 10, 2020 20:34 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 10 | $0.25 | $2.53 |
DisclosureSEC source: 0001437749-20-004693 · rdgdoc.xml · nonDerivative · entry 2 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,343 Read SEC document |
| March 09, 2020 Filed Mar 10, 2020 20:34 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 333 | $0.25 | $83.25 |
DisclosureSEC source: 0001437749-20-004693 · rdgdoc.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,333 Read SEC document |
| February 05, 2020 Filed Feb 8, 2020 02:38 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001437749-20-002098 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-02-04 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 50% of the shares underlying the option will vest upon the approval by the U.S. Food and Drug Administration of a new drug application for the Company's product candidate, KP415. The remaining 50% of the shares underlying the option will vest upon the approval of a label for KP415 which includes 30 minute onset and 13-hour duration (the "30/13 Label") as defined in the KP415 License Agreement dated September 3, 2019. Each vesting event is contingent upon such optionee's continued employment with the Issuer at the relevant vesting date as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 21:15 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $0.52 | $0.00 |
DisclosureSEC source: 0001437749-19-023643 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2029-11-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 100% of the shares underlying the option will vest upon the acceptance of a new drug application for the Company's product candidate, KP415, by the U.S. Food and Drug Administration, provided that at the relevant vesting date such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| September 24, 2019 Filed Sep 26, 2019 00:57 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 3,000 | $0.74 | $2,220.00 |
DisclosureSEC source: 0001437749-19-019060 · rdgdoc.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:36 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001437749-19-002170 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-05 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on February 6, 2020 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| October 12, 2018 Filed Oct 15, 2018 20:28 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,500 | $2.50 | $3,750.00 |
DisclosureSEC source: 0001437749-18-018301 · rdgdoc.xml · nonDerivative · entry 2 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Read SEC document |
| October 11, 2018 Filed Oct 15, 2018 20:28 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | PurchaseCommon Stock | 1,500 | $2.55 | $3,825.00 |
DisclosureSEC source: 0001437749-18-018301 · rdgdoc.xml · nonDerivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Read SEC document |
| January 25, 2018 Filed Jan 29, 2018 23:57 UTC | ZEVRA THERAPEUTICS, INC. KMPH · Entity 5212 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.50 | $0.00 |
DisclosureSEC source: 0001437749-18-001307 · rdgdoc.xml · derivative · entry 1 Sangiovanni Timothy J. · CIK 0001698328 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-01-24 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2014 Equity Incentive Plan (the "Plan"). 25% of the shares will vest on January 25, 2019 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.